amantadine ER
Selected indexed studies
- Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy. (Clin Park Relat Disord, 2022) [PMID:35059622]
- Amantadine. (, 2006) [PMID:30000367]
- Osmolex ER--another extended-release amantadine for Parkinson's disease. (Med Lett Drugs Ther, 2018) [PMID:30383732]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy. (2022) pubmed
- Amantadine. (2006) pubmed
- Osmolex ER--another extended-release amantadine for Parkinson's disease. (2018) pubmed
- Extended-Release Amantadine for Levodopa-Induced Dyskinesia. (2019) pubmed
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. (2018) pubmed
- Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. (2020) pubmed
- Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. (2021) pubmed
- The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. (2018) pubmed
- Amantadine Extended-Release (GOCOVRI(™)): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease. (2018) pubmed
- Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. (2018) pubmed